Category: Press Releases

Syncromune to Present at Piper Sandler 36th Annual Healthcare ConferenceFORT LAUDERDALE, Fla. and WEST DES MOINES, Iowa, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Syncromune® Inc., a clinical-stage biopharmaceutical company dedicated to developing innovative first in class immunotherapies for solid tumors, today announced that Charles Link, M.D., Executive Chairman of Syncromune, will deliver...

Syncromune Granted FDA Fast-Track Designation for SYNC-T SV-102 for the Treatment of Metastatic Castrate-Resistant Prostate Cancer (mCRPC)FORT LAUDERDALE, Fla., July 01, 2024 (GLOBE NEWSWIRE) -- Syncromune® Inc., a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for solid tumor cancers, today announced that the U.S. Food and Drug Administration (FDA) has...

Syncromune® Inc. Announces FDA Clearance of IND Application for SYNC-T SV-102, a First-In-Class Combination Multi-Target Immunotherapy for Metastatic Castrate-Resistant Prostate CancerSYNC-T SV-102 Therapy combines partial tumor oncolysis with a fixed-dose combination multi-target biologic drug to provide a novel, personalized therapeutic approach for the treatment of metastatic castrate-resistant prostate cancerSyncromune expects...

Syncromune® Inc. Presents Positive Results from SYNC-T™ SV-102 Phase 1 Trial at AACR Annual Meeting 2024Initial clinical data demonstrate a very high 85% overall response rate in patients with metastatic castrate-resistant prostate cancer.FORT LAUDERDALE, Fla., April 08, 2024 (GLOBE NEWSWIRE) -- Syncromune® Inc., a clinical-stage biopharmaceutical company focused on the development...

Syncromune® Inc. to Present Initial Clinical Data from SYNC-T™ SV-102 Phase 1 as a Late-Breaker at the American Association for Cancer Research Annual Meeting 2024Presentation will take place during the “Cancer Vaccines: Ready for Prime Time?” session onApril 7, from 3:00 - 5:00pm PT at the San Diego Convention CenterMarch...

Syncromune® Inc. Expands Scientific Advisory Board with Addition of Prominent Oncology Trailblazer James Armitage, M.D.Dr. Armitage is a world-renowned expert in the research and treatment of lymphoma and will serve as Advisory Board ChairOctober 31, 2023 08:00 AM Eastern Daylight Time FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Syncromune®, Inc., a clinical-stage biopharmaceutical company focused on...

Eucure and Syncromune Establish Technology Transfer Agreement for YH002 (OX40 Antibody) and Multiple Other Clinical-Stage AntibodiesBEIJING, China, August 30, 2023 – Eucure (Beijing) Biopharma Co., Ltd. (“Eucure”), a wholly owned subsidiary of Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”), announced today that the company has entered into a technology transfer agreement with...

Syncromune® Inc., Appoints Jonathan Lewis, M.D., Ph.D., A Renowned Immune Therapy Pioneer, as Chief Medical OfficerFORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Syncromune, Inc., a clinical-stage biopharmaceutical company focused on the development of SYNC-T™, a groundbreaking platform technology that synchronizes in situ neoantigen T cell education and immunostimulation via a drug/device combination therapy, proudly announces the appointment...

Syncromune, Inc. Enters into an Exclusive Worldwide License Agreement with Eucure Biopharma Co., Ltd., to Develop and Commercialize YH002 (OX40 Antibody) and Two Undisclosed Active Ingredients as Components of the Syncrovax™ Combination Immunotherapy Platform FORT LAUDERDALE, FL. and BEIJING, China, October 18, 2022 (BUSINESS WIRE) – Syncromune, Inc., a clinical...

Syncromune, Inc. to Present at the 2022 BIO CEO & Investor Conference Syncromune, Inc. to Present at the 2022 BIO CEO & Investor Conference FORT LAUDERDALE, FL., Feb. 11, 2022 (BUSINESS WIRE) -- Syncromune, Inc., a clinical stage biopharmaceutical company focused on the development of intratumoral immunotherapy announced today that...